PAWS-GIST is raising funds to set up a clinic in the UK for Paediatric, Adolescent, Wild-type & Syndromic GIST patients. Our aim being to improve treatment and ultimately find a cure for this rare form of cancer. We hope that by the end of 2012 we will be in a position to launch a PAWS-GIST […]

Imatinib (Glivec) has been accepted for restricted use within Scotland for certain high risk GIST adult patients. The SMC accepted that adjuvant imatinib for three years compared to one year significantly improved survival. However, this treatment has yet to be approved by NICE for England & Wales. Click here for full details from SMC.

This new approach to the treatment of ascites has just been approved by NICE. It comprises a catheter and collection vessel which the patient can continue to wear at home, so that he does not need to make repeated visits to hospital everytime fluid needs to be drained. Click here here to read the full text of […]

Novartis announced on 27th February that the European Commission (EC) has approved an update to the Glivec® (imatinib)* label to include 36 months of treatment after surgery for adults with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the inclusion criteria of the pivotal study. This extended treatment regimen has been shown to improve recurrence-free […]

On 1ST February AB Science published a press release announcing encouraging results from a phase2 trial of their drug masitinib. The trial compared masitinib vs sunitinib for the second-line treatment of patients with locally advanced or metastatic imatinib-resistant GIST. Members of SPAEN and clinical experts felt at the time that AB Science’s claims were premature. […]

Jayne Bressington has written a paper on PAWS GIST for the Newsletter of SIOPE (European organisation for the support of paediatric oncology). Click here to download the newsletter as a PDF. Jayne’s article is on pages 16 and 17.

Three members of GIST Support UK attended this meeting of the Sarcoma PAtients EuroNet in Berlin in November. Click here to read Jayne Bressington’s report.

We had a very successful patient meeting in London on Thursday 20th October in London. See our Video Reports of this meeting. Our next meeting will be in April 2012. This will be announced on this site when further information is available.

The assessment of Bayer HealthCare’s investigational drug regorafenib for the treatment of stomach tumoursis to be fast-tracked by US authorities for the treatment of stomach tumours Click here to read the report.

ASCO 2011 News reports that 36 months adjuvant Imatinib treatment for high risk GISTs improves recurrence-free survival (RFS) and even overall survival (OS). Click here to read the report.